Literature DB >> 3109805

Use of nitroglycerin in the treatment of acute heart failure and cardiogenic shock in patients with myocardial infarction.

N E Belskii, V A Pilipenko, S I Roshchin, A I Shira, I S Gilmar.   

Abstract

The effectiveness of nitroglycerin in the treatment of acute heart failure was investigated in 100 patients with myocardial infarction. It was found that nitroglycerin has marked advantages in comparison with cardiac glycosides both as regards its effectiveness and as regards the character of its action on the haemodynamics and the state of the periinfarction zone. In most patients (78%), a favourable effect was attained with intravenous nitroglycerin administration and with additional intake in the form of tablets. Clinical improvement was preceded by normalization of pulmonary artery pressure. Uninterrupted nitroglycerin administration was terminated after normalization and stabilization of haemodynamics. The results showed that with monitoring haemodynamics nitroglycerin can be administered also in haemodynamic disorders, which occur in the early period of cardiogenic shock.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3109805

Source DB:  PubMed          Journal:  Cor Vasa        ISSN: 0010-8650


  3 in total

Review 1.  Vasopressors for acute myocardial infarction complicated by cardiogenic shock.

Authors:  R Prondzinsky; K Hirsch; L Wachsmuth; M Buerke; S Unverzagt
Journal:  Med Klin Intensivmed Notfmed       Date:  2017-12-04       Impact factor: 0.840

Review 2.  Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome.

Authors:  Julia Schumann; Eva C Henrich; Hellen Strobl; Roland Prondzinsky; Sophie Weiche; Holger Thiele; Karl Werdan; Stefan Frantz; Susanne Unverzagt
Journal:  Cochrane Database Syst Rev       Date:  2018-01-29

3.  Vasoactive pharmacologic therapy in cardiogenic shock: a critical review.

Authors:  Rasha Kaddoura; Amr Elmoheen; Ehab Badawy; Mahmoud F Eltawagny; Mohamed A Seif; Khalid Bashir; Amar M Salam
Journal:  J Drug Assess       Date:  2021-07-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.